SenesTech (SNES) Q1 2026 earnings review
Messy Amazon Transition Masks D2C Growth, But Cash Burn Accelerates
SenesTech delivered a noisy Q1 2026. Headline revenue grew an anemic 2% YoY to $493,000, heavily distorted by a $157,000 drop in third-party e-commerce sales as the company deliberately moved Amazon operations in-house. While this strategic pivot temporarily depressed the top line, the underlying mechanics showed promise: Direct-to-Consumer (D2C) grew 42%, and B2B surged 57%. However, profitability remains a severe issue. Despite gross margins hitting a record 68.6%, a bloated SG&A line—exacerbated by severance and legal costs—drove the net loss wider to $2.1M. New CEO Michael Edell takes over a company with improving channel economics but a shrinking cash runway.
🐂 Bull Case
The short-term pain of cutting off third-party Amazon sellers is already reversing. April e-commerce sales skyrocketed 163% YoY to $146,000, proving the company can drive superior conversion and capture higher margins directly.
Gross margin expanded to a company record of 68.6%. As D2C and subscription mix increases, the underlying profitability of every unit sold is drastically improving.
🐻 Bear Case
The company added $25,000 in incremental gross profit YoY, but operating expenses ballooned by $481,000. This massive negative operating leverage makes the gross margin victory irrelevant.
The share count has exploded from 1.3M to 5.26M over the last 12 months. With cash down to $6.8M and quarterly burns accelerating past $1.6M (Adj. EBITDA), further shareholder dilution seems inevitable.
⚖️ Verdict: 🔴
Bearish. The commercial strategy under the new CEO makes strategic sense, and the April data proves D2C traction. However, the sheer scale of the operating expenses relative to revenue continues to torch cash at an unsustainable rate, negating the impressive gross margin improvements.
Key Themes
In-House Amazon Transition Drives Near-Term Pain, Long-Term Gain
The decision to eliminate third-party e-commerce management slashed Q1 third-party revenue from $157k to just $17k. However, this is Reversing rapidly. By taking direct control, the company achieved better pricing visibility and margin capture. April data vindicates the move: e-commerce generated a record $146k (up 163% YoY and 47% sequentially from March).
Subscriptions: Building a Recurring Base
Subscription revenue is Accelerating, growing 44% YoY to $56k in Q1. The momentum continued into April, where subscription sales hit a record $36k for the month alone (up 198% YoY). By locking in customers to the Evolve non-poison ecosystem, SenesTech is smoothing out its highly erratic historical revenue curve.
Expense Bloat Contradicts Margin Narrative
Management heavily promoted their record 68.6% gross margin, but an analysis of the income statement reveals this is an illusion of profitability. Gross profit increased by a mere $25,000 YoY, while Selling, General and Administrative (SG&A) expenses surged by $477,000. Even backing out $443,000 in one-time legal and severance costs, core operating expenses are suffocating the business model.
NYC Municipal Pilot Dependency
A crucial catalyst for the company has been its municipal pilot programs, specifically the 12-month New York City rat contraception pilot concluding this month. The company has historically leaned heavily on this narrative, yet B2B revenues (while up 57% YoY) are still only $298k. If the NYC pilot does not convert into a massive, multi-year procurement contract immediately, the municipal growth thesis will fracture.
Leadership Shift Indicates Commercial Focus
The appointment of Michael Edell as CEO signals a definitive pivot from scientific R&D to rigorous commercial execution. His immediate moves—taking Amazon in-house, redesigning the Shopify store, and launching a packaging refresh—target conversion rates and customer retention rather than simply proving the technology works. The macro environment, characterized by increasing regulatory pushback against traditional poisons, provides a strong tailwind for this commercial strategy.
Other KPIs
Accelerating. Up 57% YoY from $190,000. This segment reflects growing traction across distributors, municipal deployments, and professional pest management channels, indicating that commercial operators are increasingly willing to trial non-lethal solutions.
Decelerating profitability. The loss widened from $1.46M in Q1 2025. Despite top-line stabilization and record gross margins, the core cash burn continues to worsen, primarily driven by heightened SG&A overhead.
Reversing. Down from $7.57M at the end of 2025 and significantly down from the $10M+ levels touted in mid-2025. Given the current burn rate, the company has roughly 4 quarters of runway left before requiring another highly dilutive capital raise.
Guidance
Accelerating. With the Amazon transition completed in March, April sales surged 163% YoY and 47% sequentially. This effectively de-risks the Q1 disruption and points to a much stronger Q2 direct-to-consumer performance.
Accelerating. Up 198% YoY. Subscription-based customers increased 109%, validating management's effort to build a recurring revenue stream around the Evolve product line.
Key Questions
Path to Breakeven
With cash down to $6.8 million and Adjusted EBITDA burn exceeding $1.6 million per quarter, what is the exact revenue threshold required to achieve cash-flow breakeven, and what is the timeline to get there?
NYC Pilot Conversion
The 12-month New York City pilot concludes this month. What specific metrics is the city using to evaluate success, and when should investors expect a formal decision regarding a city-wide commercial contract?
SG&A Rationalization
Even excluding the $443,000 in severance and legal costs, operating expenses remain incredibly high relative to revenue. Are there further cost-cutting measures planned to bring SG&A in line with the current scale of the business?